Juvenile macular degeneration Therapeutic and Drug Pipeline Review H2

Pune, India, 24th August 2017: WiseGuyReports announced addition of new report, titled “Juvenile Macular Degeneration (Stargardt Disease) – Pipeline Review, H2 2017”.

Summary

Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease. Stargardt’s disease is an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision, dark, empty spots in the center of vision and difficulty reading or performing detail work. Risk factors include arteriosclerosis, hypercholesterolemia, smoking and hypertension.

 

GET SAMPLE REPORT @https://www.wiseguyreports.com/sample-request/1927008-juvenile-macular-degeneration-stargardt-disease-pipeline-review-h2-2017

 

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Juvenile Macular Degeneration (Stargardt Disease) – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

The Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 5, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

 

Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology).

– The pipeline guide reviews pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology)

 

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 

Table of Content: Key Points

List of Tables

List of Figures

Introduction

Juvenile Macular Degeneration (Stargardt Disease) – Overview

Juvenile Macular Degeneration (Stargardt Disease) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Juvenile Macular Degeneration (Stargardt Disease) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Juvenile Macular Degeneration (Stargardt Disease) – Companies Involved in Therapeutics Development

Acucela Inc

Alkeus Pharmaceuticals Inc

Astellas Pharma Inc

Copernicus Therapeutics Inc

Grupo Ferrer Internacional SA

Iris Pharma

Nemus Bioscience Inc

Ophthotech Corp

ProQR Therapeutics NV

Sanofi

…Continued        

 

ACCESS REPORT @https://www.wiseguyreports.com/reports/1927008-juvenile-macular-degeneration-stargardt-disease-pipeline-review-h2-2017  

                                 

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: https://twitter.com/WiseGuyReports                                                                  

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts    

Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: sales@wiseguyreports.com
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India
Website: www.wiseguyreports.com